+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Memantine"

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Thumbnail Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • December 2024
  • 125 Pages
  • Global
From
From
From
Alzheimer's Drugs Market Report 2025 - Product Thumbnail Image

Alzheimer's Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Neurological Disorder Drugs Market Report 2025 - Product Thumbnail Image

Neurological Disorder Drugs Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
From
Alzheimer's Disease Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Alzheimer's Disease Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
Alzheimer's Drugs Market Report and Forecast 2024-2032 - Product Thumbnail Image

Alzheimer's Drugs Market Report and Forecast 2024-2032

  • Report
  • October 2024
  • 250 Pages
  • Global
From
From
Vascular Dementia - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Dementia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Alzheimer's Drugs - A Global Market Overview - Product Thumbnail Image

Alzheimer's Drugs - A Global Market Overview

  • Report
  • September 2024
  • 253 Pages
  • Global
From
Alzheimer's Therapeutics Market Report 2022-2032 - Product Thumbnail Image

Alzheimer's Therapeutics Market Report 2022-2032

  • Report
  • December 2022
  • 196 Pages
  • Global
From
From
Loading Indicator

Memantine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is classified as an NMDA receptor antagonist, which works by blocking the action of a neurotransmitter called glutamate. This helps to reduce the symptoms of dementia, such as memory loss, confusion, and difficulty with language. Memantine is also used to treat Parkinson's disease, Huntington's disease, and multiple sclerosis. Memantine is a relatively new drug, having been approved by the FDA in 2003. It is available in both oral and intravenous forms, and is typically prescribed in combination with other drugs. It is generally well-tolerated, with few side effects. The memantine market is a growing one, with a number of companies offering products. These include Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies, such as Actavis, Lupin, and Dr. Reddy's Laboratories, also offer generic versions of the drug. Show Less Read more